Find your peptide and see the side effects people report. Tap an entry for routes, evidence and sources.
Reports do not establish the cause or how often a reaction happens. When to get help →
Jump to a peptide
19 entries · A–Z · Tap + for details
BPC-157Anxiety, sleep changes, headache and dizziness.
Community reports
Route described: Routes vary or are unstated; the BPC/TB account explicitly describes injection under the skin.
What people report: Anxiety, trouble sleeping, headache and dizziness appear in the linked accounts.
How to read that: One account used BPC-157 with TB-500, so it cannot isolate BPC-157. Other medicines, health conditions and product contents were not independently checked.
Evidence: These are accounts of symptoms after use, not proof of causation or a reliable estimate of how often they occur.
CagrilintideNausea, constipation and difficulty eating enough.
Human trial + community reports
Route described: Injection under the skin; the public discussion includes co-use with retatrutide.
What people report: Nausea, constipation and difficulty eating enough appear in the reviewed public discussion.
How to read that: Because the writers also describe retatrutide, their accounts cannot isolate cagrilintide or validate a combination regimen.
Evidence: A 2021 randomized cagrilintide-alone trial documented nausea, constipation, diarrhea and administration-site reactions. Cagrilintide and a cagrilintide/semaglutide combination are different study treatments.
CJC-1295 no DAC + ipamorelinFlushing, itching, local bumps and tingling; reports involve different formulations.
Community reports + FDA safety information
Route described: Injection under the skin; distinguish no-DAC blends from long-acting CJC-1295 with DAC.
What people report: Flushing, itching, raised injection-site lumps and tingling appear in public discussions. One no-DAC blend account describes hand tingling, restlessness and chest pressure.
How to read that: A blend cannot tell us which ingredient caused a reaction. These accounts do not establish a histamine reaction or explain an individual symptom.
Evidence: FDA identifies increased heart rate and systemic vasodilatory reactions with CJC-1295. That does not make tingling or chest symptoms harmless or establish a rate for this no-DAC blend.
EpitalonTrouble sleeping, headache and next-day drowsiness; experiences vary.
Community reports
Route described: The discussion includes injection under the skin; some comments do not state the route or use other compounds.
What people report: Sleep reports conflict: some describe better sleep, while others describe sleeplessness, mild headache or next-day drowsiness.
How to read that: The linked thread includes different products and combinations. Its positive and negative stories do not establish a predictable sleep response.
Evidence: This is anecdotal experience, not an established side-effect rate. FDA identifies insufficient safety information for the proposed route.
GHK-CuStinging, burning and soreness after injection, sometimes delayed.
Community reports
Route described: Injection under the skin; these reports do not describe a cosmetic cream.
What people report: Burning, stinging and soreness, sometimes starting later rather than during the injection. Other writers report no sting at all.
How to read that: The same sensation does not happen to everyone. A sting cannot verify identity, purity or effectiveness.
Evidence: Human safety data for injectable GHK-Cu are limited. Claims that every sting is caused by acidity, copper or a histamine response are not established by these posts.
GLOWBurning, itching, welts and lingering soreness after blend injections.
Blend reports
Route described: Injection under the skin; these are self-described blend products.
What people report: Writers describe burning, itching and welts after products called GLOW, sometimes with longer-lasting soreness.
How to read that: GLOW contains multiple ingredients. A report after the whole blend does not identify GHK-Cu, BPC-157 or TB-500 as the cause.
Evidence: Ingredient research does not establish the safety of the finished blend. The linked discussion does not independently verify its vial contents.
GlutathioneStinging, itching, swelling and soreness after injection under the skin.
Community reports + FDA safety alert
Route described: The public account describes injection under the skin; the FDA investigation concerns intravenous infusions.
What people report: Stinging, itching, swelling and soreness at the injection site appear in the public account.
How to read that: An IV contamination alert is a different situation from a local skin reaction. Neither can diagnose an individual bump.
Evidence: FDA investigated nausea, vomiting, chills and other serious reactions after contaminated IV glutathione products and confirmed excessive endotoxin in tested material.
KLOWBurning, welts and, in some accounts, diarrhea after blend use.
Blend reports
Route described: Injection under the skin; these are self-described blend products.
What people report: Public KLOW accounts include burning and welts. A separate gut-symptom discussion includes a KLOW user reporting diarrhea.
How to read that: KLOW contains four ingredients. The discussion itself questions whether KPV can be singled out; it cannot from that account.
Evidence: Adding KPV is not established here as a way to prevent allergy or make another ingredient safer.
KPVBloating, constipation or diarrhea; other people report no unwanted effects.
Community reports
Route described: The constipation discussion includes oral use; the diarrhea discussion explicitly includes injection.
What people report: Bloating and constipation appear in one discussion; diarrhea or loose stools appear in another. Other writers report none of those problems.
How to read that: Some accounts involve tirzepatide, retatrutide or a multi-ingredient blend. Route and co-use matter.
Evidence: FDA reports no identified human exposure data in its cited safety review. Forum accounts do not fill that clinical evidence gap.
Melanotan IINausea, flushing and darker or newly noticed moles.
Community reports + regulator information
Route described: The selected discussions describe injections. Nasal products are not the same exposure.
What people report: Nausea, flushing and darker or newly noticed moles appear in public accounts.
How to read that: A changing mole needs assessment rather than being assumed to be an expected cosmetic effect.
Evidence: Australia’s TGA warns about nausea, vomiting, facial redness and mole changes, alongside serious reported harms. This does not establish that melanotan caused a particular skin cancer.
MOTS-CItchy bumps, fatigue and body or joint aches.
Community reports
Route described: Injection under the skin; several accounts also use other compounds.
What people report: Itchy delayed bumps, fatigue and body or joint aches appear in the reviewed discussion. A separate discussion includes reports of throat swelling.
How to read that: Throat swelling belongs in the urgent-help category below, regardless of a forum explanation. Adding another compound does not establish protection from an allergic reaction.
Evidence: The reports do not establish frequency or cause. FDA notes a lack of identified human exposure data in the cited safety review.
NAD+Burning or soreness after injection; some people report no sting.
Community reports + FDA safety alert
Route described: The public thread includes injection and IV experiences; read each account separately. NAD+ is not a peptide.
What people report: Burning and soreness after injections are described, alongside accounts of no reaction. IV experiences in the same discussion are not interchangeable with shots under the skin.
How to read that: A burning sensation cannot identify the cause or verify that the product is sterile.
Evidence: FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injectables, consistent with excessive endotoxin. Those symptoms are not evidence of a helpful detox response.
PT-141 / bremelanotideNausea, flushing and headache; also documented for prescription Vyleesi.
Community reports + prescription label
Route described: Vyleesi is injected under the skin. Public discussions also include nasal and independently sourced products.
What people report: Nausea, flushing and headache appear in the public discussion, with differing severity.
How to read that: The Vyleesi label applies to that finished prescription medicine and its studied population, not every vial or nasal spray sold as PT-141.
Evidence: In Vyleesi trials involving premenopausal women with HSDD, nausea occurred in 40.0% versus 1.3% with placebo; flushing in 20.3% versus 0.3%. The label also warns about temporary blood-pressure increases and skin darkening.
Retatrutide (JD-3RT)Sore or unusually sensitive skin in public reports; digestive symptoms in trials.
Human trial + community reports
Route described: Trial injections and independently sourced products must be distinguished; the public writer describes trial participation, which is not independently verified.
What people report: Public discussions describe unusually sensitive or sore skin. One writer describes tenderness across the arms and legs.
How to read that: A public post does not verify trial assignment or explain an individual symptom. Digestive symptoms are also documented in controlled research.
Evidence: TRIUMPH-2 reported more nausea, diarrhea and altered skin sensation (dysesthesia) with retatrutide than placebo. Retatrutide remains investigational; trial findings do not validate an independently sold vial.
SelankHeadache, dizziness, stomach discomfort or increased anxiety in injection accounts.
Community reports
Route described: The selected account describes injection; it should not be treated as evidence about nasal use.
What people report: One writer describes headache, dizziness, stomach discomfort and feeling more anxious after an injection; another reports similar symptoms.
How to read that: The writer later says other substances might have contributed. The account does not establish a mechanism.
Evidence: A report that a product is intended to calm anxiety does not exclude an unwanted experience. Frequency remains unknown.
TB-500Fatigue, trouble sleeping, rash or joint pain; other people report none.
Community reports
Route described: Injection; one linked account specifies injection under the skin with BPC-157.
What people report: A TB-500 discussion describes fatigue, trouble sleeping, rash and joint pain. Another writer in the same discussion reports none of those symptoms.
How to read that: A separate BPC/TB account describes anxiety and chest tightness. Co-use prevents attributing that experience to TB-500 alone.
Evidence: The reviewed accounts do not establish a human side-effect rate. Research on full-length thymosin beta-4 cannot automatically be applied to every product called TB-500.
TesamorelinSwollen or numb hands and tingling; fluid retention is also documented for Egrifta WR.
Community reports + prescription label
Route described: Injection under the skin; online accounts include independent products and blends.
What people report: Swollen or numb hands and tingling appear in public discussions. Some writers also used ipamorelin or retatrutide.
How to read that: Co-use limits what can be attributed to tesamorelin. Persistent numbness deserves medical assessment.
Evidence: The Egrifta WR label describes fluid retention, joint discomfort, carpal tunnel symptoms, injection-site reactions, blood-sugar changes and hypersensitivity. This is evidence about the named prescription product.
Tirzepatide (JD-2TR)Itchy red injection marks in public reports; nausea, diarrhea, vomiting and constipation in Zepbound trials.
Community reports + prescription label
Route described: Injection under the skin; distinguish Zepbound/Mounjaro from compounded or research-vial products.
What people report: Public accounts describe red, itchy injection-site marks, including reactions beginning after earlier injections caused none.
How to read that: The linked accounts describe different sources. A prior reaction-free period cannot establish that a new reaction is harmless.
Evidence: The Zepbound label lists nausea, diarrhea, vomiting, constipation and injection-site reactions. Local reactions occurred in 6–8% across the studied dose groups versus 2% with placebo. Those rates apply to the label’s trial populations.
Wolverine (BPC-157 + TB-500)Vivid dreams, anxiety, palpitations, headache, dizziness and nausea in public blend accounts.
Community blend reports · reviewed October 30, 2026
Route described: Injection in the selected accounts; products and exact contents were not independently verified.
What people report: A June 27, 2026 writer naming a 5 mg + 5 mg blend described vivid dreams and a racing heartbeat or palpitations. A May 23, 2026 account described dizziness, headache and nausea. Replies include anxiety and reports of no unwanted effects.
How to read that: These accounts cannot identify the responsible ingredient, establish causation or tell how often a reaction occurs. They are not verified reports about the JD BioWorks product. A new symptom is not proof that healing is happening.
Evidence: FDA’s May 2026 BPC-157 review found insufficient clinical safety information to characterize its safety profile. That review does not establish a side-effect rate for Wolverine. See when to get help.
Why reactions vary & what to record
The active ingredient, other ingredients, product quality, route, other substances and an individual’s health can all affect interpretation. In particular, FDA has documented contamination-related reactions with some injectable products. That is different from proving the cause of a particular person’s symptoms.
Keep the product name, formulation, batch, route, amount used, timing of symptoms, photos of changes, and a list of other medicines or supplements available for a clinician. A product-quality concern can also be reported through FDA MedWatch.
Forum fixes are not verified treatments. We do not turn suggestions to add water, mix compounds, change routes, take an antihistamine or “push through” into instructions. Those suggestions do not establish that repeating an exposure is safe.
How we researched this page
Sources checked October 27, 2026. We searched public discussions for the 18 compounds in the PeptideWhy library and read the linked first-person accounts and relevant replies. We separated reported symptoms from commenters’ theories and advice, kept route and combination use visible, and checked clinical claims against primary studies, prescription labels, FDA and TGA information.
This is a targeted editorial review, not a systematic review, representative survey or diagnosis. Writers, products and reported outcomes were not independently verified. The number of posts is not a side-effect rate; selected experiences may overrepresent problems. Some people report no unwanted effects. Missing reports do not establish safety. Sources may change or disappear.
Prescription-label findings apply to the named finished medicine. They do not approve or verify separately sold research products. What “research use only” means → · Suggest a correction →
Compiled by PeptideWhy · Original entries checked October 27, 2026; Wolverine added and checked October 30, 2026 · Educational information, not an individual diagnosis.